Survival of the APL mice treated by ATRA in combination with the specific PML-RARA as well as with the non-specific pVAX14 was significantly (p < 0.0001 and p < 0.0014, respectively) superior to that of the mice treated by ATRA alone (Figure 1B, Supplementary Table S1). The gene discussed is PML; the disease is acute promyelocytic leukemia.